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Abstract
The adhesion G-protein coupled receptor Adgrg6 (formerly Gpr126) is instrumental in the
development, maintenance and repair of peripheral nervous systemmyelin. The prion pro-
tein (PrP) is a potent activator of Adgrg6 and could be used as a potential therapeutic agent
in treating peripheral demyelinating and dysmyelinating diseases. We designed a dimeric
Fc-fusion protein comprising the myelinotrophic domain of PrP (FT2Fc), which activated
Adgrg6 in vitro and exhibited favorable pharmacokinetic properties for in vivo treatment of
peripheral neuropathies. While chronic FT2Fc treatment elicited specific transcriptomic
changes in the sciatic nerves of PrP knockout mice, no amelioration of the early molecular
signs demyelination was detected. Instead, RNA sequencing of sciatic nerves revealed
downregulation of cytoskeletal and sarcomere genes, akin to the gene expression changes
seen in myopathic skeletal muscle of PrP overexpressing mice. These results call for cau-
tion when devising myelinotrophic therapies based on PrP-derived Adgrg6 ligands. While
our treatment approach was not successful, Adgrg6 remains an attractive therapeutic target
to be addressed in other disease models or by using different biologically active Adgrg6
ligands.
Introduction
The prion protein (PrP), encoded by the PRNP gene, is mainly known for its role as the causa-
tive infectious agent in prion diseases, a group of fatal neurodegenerative diseases. Yet the
remarkable evolutionary conservation of PrP suggests that it exerts physiological functions.
Mice ablated for PrP [1,2] and goats lacking PrP due to a naturally occurring mutation [3]
develop a progressive peripheral demyelinating neuropathy, indicating that PrP is involved in
myelin maintenance. Although no mutations in the human PRNP gene were found in a study
of patients with hereditary neuropathies [4], the alteration of PrP or its sequestration in aggre-
gates could explain the development of peripheral neuropathy in patients suffering from
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Creutzfeldt-Jakob disease [5]. This notion is supported by the occurrence of pronounced
peripheral demyelination in certain genetic forms of Creutzfeldt-Jakob disease [6]. Moreover,
a patient with two pathogenic PRNPmutations was reported to develop an early onset periph-
eral demyelinating neuropathy [7].
The mechanism by which PrP exerts its function in myelin maintenance has recently been
identified [8]. The N-terminal fragment, termed flexible tail (FT), comprises the myelino-
trophic domain of PrP. FT is released by proteolysis and activates the adhesion G-protein cou-
pled receptor Adgrgr6 on Schwann cells. Both in vitro and in vivo, activation of Adgrg6 by a
peptide derived from FT results in cAMP accumulation and promyelinating signaling. In the
peripheral nervous system (PNS), Adgrg6 is crucial for the development of the myelin sheath
in zebrafish [9] and mice [10]. In addition, Adgrg6 is involved in the remyelination of axons
[11] and reinnervation of neuromuscular junctions [12] after nerve injury. Whereas the induc-
ible knockout of Adgrg6 in Schwann cells did not result in signs of demyelination for up to 4
months [11], aged conditional Adgrg6 knockout mice showed neuromuscular junction alter-
ations and signs of denervation in hindlimbs, consistent with chronic disruption of Schwann
cell function [12]. Together with the late-onset demyelinating neuropathy of PrP knockout
mice, these findings suggest that Adgrg6 is not only required for the initiation of myelination,
but also for long-term myelin maintenance.
The role of Adgrg6 in myelination and remyelination suggests that it could be a promising
therapeutic target for peripheral demyelinating diseases and possibly other diseases linked to
Adgrg6 malfunction, such as adolescent idiopathic scoliosis [13]. We therefore set out to
explore the therapeutic potential of stimulating Adgrg6-dependent promyelinating pathways
using its natural ligand PrP. To this end, we constructed a dimeric fusion protein consisting of
the FT linked to crystallizable fragment (Fc) of immunoglobulin G1 (FT2Fc). FT2Fc showed
favorable pharmacokinetic properties in vivo including a half-life of 45 h but failed to have a
therapeutic effect on the early molecular signs of demyelination in PrP knockout mice.
Instead, gene expression analysis of sciatic nerves from mice treated with FT2Fc revealed unex-
pected changes in cytoskeletal and contractile elements. The observed transcriptomic changes




Breeding and maintenance of mice was performed in specified-pathogen-free facilities at the
University Hospital Zurich. Mice were housed in groups of 3–5, under a 12 h light/12 h dark
cycle, with sterilized chow food and water ad libitum. The protocols for animal care and exper-
iments were in accordance with the Swiss Animal Protection Law. All experiments were
approved by the Veterinary Office of the Canton of Zurich (permits ZH139/2016 and ZH201/
2018). For experiments with FT2Fc, male and female C57BL/6J (WT) and PrP knockout
(ZH3) mice were used. Mice were intravenously or intraperitoneally injected with various dos-
ages of FT2Fc, mIgG (5–10 mg/Kg bodyweight), sodium phosphate buffer (20 mM, pH 7), FT
or control peptide. Blood samples were collected from the saphenous vein and serum was
obtained by centrifugation of clotted blood for 1.5 min at 10’000 g. For the pharmacokinetic
studies and acute treatment experiment, adult mice were used. Chronic treatment was started
at 1 month of age and lasted for 4 months.
Transgenic mice expressing a ubiquitous promoter (CAG), a reporter gene-stop cassette
(CAT) flanked by loxP sites, and Prnp were bred with mice expressing tamoxifen-inducible
Cre recombinase under the control of the human ACTA1 (Actin, alpha 1, skeletal muscle)
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promoter (C57BL/6J-Tg(CAG-cat,-Prnp)56Aag x Tg(ACTA1- cre/Esr1�)2Kesr/J). Tamoxifen-
induced Cre-Lox recombination in skeletal muscle cells removed the stop-cassette and allowed
for Prnp overexpression by the CAG promoter. Mice were fed food pellets with 400 mg/kg
tamoxifen (Envigo) for one week to induce Cre-recombination. Male mice were sacrificed for
organ collection 14 days after induction. CAG+/Cre+ mice were compared to CAG+/Cre-,
CAG-/Cre+ and CAG-/Cre- mice. For collection of organs, mice were sacrificed by cervical
dislocation in deep anesthesia.
Electrophysiological investigations
Electrophysiological investigations were performed on the sciatic nerve of mice treated with
FT2Fc or control treatment. Mice were anesthetized with Ketamine-Xylazine and electrophysi-
ological investigations were performed as previously described [16,17]. The investigators were
blinded as to the treatment and strain of the mice during the tests as well as post-hoc analyses.
Morphological analysis
For toluidine blue stained sections, sciatic nerves were dissected and incubated in 4% glutaral-
dehyde in 0.1 M sodium phosphate buffer pH 7.4 at 4˚C overnight. Tissue was embedded in
Epon using standard procedures and semithin sections (500 nm) were stained with toluidine
blue. Counting of myelinated axons was performed manually on one 313 x 197 μM field of
view per mouse with the observer blinded as to the treatment group. Then number of myelin-
ated axons was normalized to the area. For cryosections of gastrocnemius muscle, the tissue
was frozen in Optimal Cutting Temperature compound using liquid nitrogen and cut in
10 μM sections at the cryostat. Slides were incubated in 4% paraformaldehyde for 10 min and
washed three times in PBS. The sections were first incubated in hematoxylin for 10 min, and
then in trichrome staining solution (Chromotrope 2R 0.6% w/v (Chroma 1B259), fast green
FCF 0.3% w/v (BDH 340304F), phosphotungstic acid 0.6% w/v, acetic acid 0.5%, pH 3.4) for
20 min. Finally, the sections were incubated in 0.5% acetic acid for differentiation and dehy-
drated in ethanol.
Cell culture
Wild type SW10 cells and SW10 cells devoid of Adgrg6 were grown in DMEM (Gibco) supple-
mented with 10% FBS, penicillin-streptomycin and glutamax (Invitrogen) at 33˚C. FreeSty-
leTM 293-F (Thermofisher, R790-07) cells were grown in FreeStyle medium (Thermofisher,
12338018) on an orbital shaker (140 rpm) at 37˚C.
Transfection
The mammalian expression vector for FT2Fc was obtained from ATUM (vector pD2610-v1).
293-F cells were seeded 2–3 h before transfection at a density of 1x106 cells per ml in Freestyle
medium supplemented with 0.2% w/v HyClone Cell Boost (GE Healthcare, SH30584.02). For
transient transfection, 1 μg of plasmid and 2 μl of 40 kD linear polyethyleneimine (1 mg/ml,
Polysciences, 24765–1) were used per milliliter of cells. For protein production, cells were sup-
plemented with 2% w/v HyClone every 2–3 days (10% of culture volume each time). At 7 days
post transfection, cell culture supernatant was cleared by centrifugation at 2’500 g for 10 min
at 4˚C. The medium was sterile filtered and stored at 4˚C or –20˚C until further processing.
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Protein purification
Cell culture supernatant was diluted 1:1 in binding buffer (0.16 M sodium phosphate, 500 mM
NaCl, pH 9) and loaded on a Protein A Sepharose (Sigma Aldrich, 17-1279-03) column at a
flow rate of 2 ml/min. After washing with 5 column volumes of binding buffer until a stable
baseline was reached, FT2Fc was eluted with elution buffer (0.1 M sodium citrate, pH 2.7).
500 μl fractions were collected and immediately neutralized with 50 μl 1 M Tris/HCl, pH 8.
Elution fractions were analyzed by 12% or gradient 4–12% NuPAGE Bis-Tris gels (Invitrogen)
followed by Coomassie staining. Fractions containing purified protein were pooled and dia-
lyzed overnight against storage buffer (0.02 M sodium phosphate, pH 7) in a 10 kD cut off dial-
ysis cassette (ThermoFisher, 66380). Purified protein was stored at 4˚C for use within days or
at –20˚C for longer-term storage.
RNA extraction, library preparation and sequencing
For sciatic nerves, total RNA was extracted using TRIzol (Invitrogen Life Technologies,
15596–018) according to the manufacturer’s instructions. The phenol-chloroform phase was
subsequently used for protein extraction. For RNA extraction of tibialis muscle from PrP over-
expressing mice, the tissue was snap-frozen in liquid nitrogen and ground using the CryoGrin-
derTM kit system following the manufacturer’s instructions. The RNA was extracted using the
RNeasy Plus Universal Kit (Qiagen). Library preparation, RNA sequencing and bioinformatic
analysis were performed at the Functional Genomics Center Zurich (FGCZ). For sciatic nerves
of untreated 4 months old mice and tibialis muscle of PrP overexpressing mice, library prepa-
ration and RNA sequencing were performed as described previously [18]. For mice in the
chronic treatment experiment and 13–15 months untreated old mice, libraries were prepared
using the TruSeq RNA stranded Library Prep Kit (Illumina, lnc) and sequencing was per-
formed on the Illumina Novaseq 6000 instrument for single-end 100 bp reads.
RNA sequencing data analysis
For all samples, quality of reads was checked with FastQC. Reads were aligned to the GRCm38
genome assembly with Ensembl gene annotations with STAR [19]. Reads were counted with
the featureCounts [20] function from the R package Rsubread. Differential expression analysis
was performed with the R package EdgeR [21], using a generalized linear model with Trimmed
Means of M-values (TMM) normalization. In the group pair-wise comparisons, we considered
only genes with at least 10 raw counts in at least 50% of the samples in one of the groups.
Genes with false discovery rate (FDR) below 0.05 were defined as differentially expressed. For
the clustering analysis, the hclust function from the stats package was used. Visualizations
were generated with the Sushi data analysis framework [22] provided by FGCZ or with R (ver-
sion 3.5.2).
Western blot analysis
SW10 cells were lysed in ice-cold lysis buffer (phosSTOP (Sigma, 4906845001) and protease
inhibitor (Sigma, 11836153001) in RIPA buffer). Mouse organs were homogenized in lysis
buffer using stainless steel beads. The lysates were centrifuged for 10 min at 10’000 g to remove
debris. Protein concentration was measured with BCA assay (Thermo Scientific) and equal
amounts of protein for each sample (10–30 μg unless otherwise noted) were boiled in 4 x LDS
(Invitrogen) at 95˚C for 5 min. Mouse serum was diluted 1:10 in PBS and boiled in 4 x LDS
with 0.1 M dithiothreitol (DTT) for western blotting. The samples were loaded on 12% or gra-
dient 4–12% NuPAGE Bis-Tris gels (Invitrogen). Electrophoresis was performed at 200 V.
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Gels were transferred to PVDF membranes with the iBlot system (Life Technologies). Mem-
branes were blocked with 5% non-fat milk in PBS-T (for Fab83 staining) or 5% SureBlock
(LuBioScience GmbH, SB232010) in TBS-T for all other staining. Then, membranes were
incubated over night at 4˚C with the primary antibody diluted in blocking buffer. After three
washes for 10 min, membranes were incubated with secondary antibodies coupled to horse-
radish peroxidase for 1 h at room temperature (RT). After washing, membranes were devel-
oped with Crescendo chemiluminescence substrate system (Sigma, WBLUR0500) and signals
were detected using a Fusion Solo S imaging system (Vilber). Densitometry was performed
using the FusionCapt Advance software. Dashed lines indicate removal of irrelevant lanes by
image splicing from single blots. Original, uncropped images are shown in the Supporting
Information (S1 Fig).
The following primary antibodies were used for western blotting: phospho-AKT (1:1000,
Cell Signaling Technologies, 4060S), AKT (1:1000, Cell Signaling Technologies, 4685S), GFAP
(1:2000, Cell Signaling Technologies, 12389S), c-Jun (1:1000, 9165s), Egr2 (1:2000, Abcam,
ab108399), Calnexin (1:2000, Enzo, ADI-SPA-865-D), Actin (1:10’000, Milipore, MAB1501R).
In addition, we used an in-house produced Fab-fragment directed against the N-terminus of
PrP [23] (Fab83, 6 μg/ml). The following horseradish peroxidase coupled secondary antibodies
were used: anti-mouse IgG (1:10’000, Jackson Immuno Research, 115-035-003), anti-rabbit IgG
(1:4000, Jackson Immuno Research, 111-035-003), anti-human Fab (1:7000, Sigma, A0293).
Enzyme-linked immunosorbent assay (ELISA)
384-well plates were coated with Fab83 (150 nM) or equimolar amount of BSA in PBS-T over-
night at 4˚C. After three washes with PBS-T, plates were blocked with superblock (Thermo-
fisher, 37515) for 2 h at RT. Next, a serial dilution of cell culture supernatant from transfected
cells was incubated for 2 h at RT. After washing, goat anti-mouse IgG antibodies coupled to
horseradish peroxidase (1:1000, Jackson Immuno Research, 115-035-003) were added for 1 h.
Then, the plates were washed and developed with TMB (Invitrogen, SB02). The reaction was
stopped with 0.5 M H2SO4 and absorbance at 450 nm was measured in a plate reader (Perkin
Elmer, EnVision). The experiment was performed with technical duplicates.
Immunoprecipitation
Immunoprecipitation (IP) of FT2Fc from cell culture supernatant was performed as previously
described with minor modifications [23]. Briefly, sheep-anti mouse IgG paramagnetic beads
(Dynal, 11201D) were coupled with anti-His mAb (Invitrogen, 37–2900) in coating buffer
(PBS plus 0.1% immunoglobulin-free BSA) for 2 h at RT on a rotating wheel. Three molar
excess of His-tagged Fab83 were added. After 1 h incubation, beads were washed three times
with coating buffer. Cell culture supernatant was diluted 1:1 in IP buffer (50 mM Tris-Cl, 75
nM NaCl, 1% Igepal, protease inhibitor mixture (Sigma, 11836153001), pH 7.4) plus 0.5% BSA
and incubated with 50 μl of Fab83-anti-His antibody coupled beads. The same input was used
for all conditions. IP was performed overnight at 4˚C. After five washes with 50 mM Tris-Cl,
0.5% Igepal, 150 nM NaCl, 0.5% BSA, pH 7.4, elution of immunoprecipitated FT2Fc was per-
formed by incubation with peptides (200 molar excess compared to Fab83) for 2 h at 4˚C. The
eluate was boiled in 4 x LDS for western blotting. After elution, the beads were boiled in 4 x
LDS and the supernatant was investigated by western blotting.
Thermal shift assay
FT2Fc (1 μg) was diluted in 20 μl of 20 mM sodium phosphate, pH 7, with a final concentration
of 10x SYPRO orange (Sigma, S5692). The temperature was increased from 25˚C to 95˚C at
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3˚C per minute and fluorescence was measured at 610 nm in a Rotor-Gene Q thermocycler
(Qiagen). The experiment was performed in technical triplicates. The fluorescence-tempera-
ture curves were fitted to the Boltzmann equation using GraphPad Prism (version 8.4.2) to
determine the inflection point, which corresponds to the melting temperature.
cAMPmeasurements
cAMP levels were measured as previously described [8] using a colorimetric competitive
immunoassay (Enzo Life Sciences). Briefly, SW10 cells were plated in 6-well plates to ~50%
density. Cells were incubated with FT2Fc, FT or control treatment for 20 min and then lysed
with 0.1 M HCl buffer for 20 min. The lysate was cleared by centrifugation at 600 g for 10 min
and then processed according to the manufacturer’s protocol.
Experimental design and statistical analysis
GraphPad Prism software (version 8.4.2) was used for statistical analysis and data processing
except for RNA sequencing data analysis. Normal distribution and equal variances of data were
assumed, but this was not formally tested due to small n values. For the chronic treatment study,
the sample size was determined with a power calculation based on the results from our previous
electrophysiological studies [1]: at least 10 mice per group were required to detect a 6 m/s differ-
ence in motor nerve conduction velocity between treatment groups assuming a standard devia-
tion of 4.4 m/s (power 90%, type I error 5%). For all other experiments, sample sizes were chosen
according to sample sizes generally used in the field. For curve fitting, we used four-parameter
logistic regression analysis or nonlinear least-squares analysis as indicated in the figure legends.
As a measure for the goodness of fit we reported R2 for nonlinear regression as computed by
GraphPad Prism. Comparisons of two groups were performed by unpaired or paired two-tailed
t-test as indicated. For comparison of three or more groups, one- or two-way ANOVA followed
by multiple comparison tests were used and p-values were reported as multiplicity adjusted p-val-
ues. We used Sidak’s multiple comparison test for comparison of preselected independent pairs,
Bonferroni’s multiple comparisons test when the assumption of independence could not be sup-
ported, and Dunnett’s method for comparison of multiple groups to one control group. P-
values< 0.05 were considered statistically significant. P-values are indicated in graphs as �:
p< 0.05, ��: p = 0.01–0.05, ���: p = 0.001–0.01, ����: p< 0.0001. ns = not significant, p> 0.05.
Error bars in graphs show SEM. For in vitro experiments, individual points in the graphs corre-
spond to independent experiments (cAMP assay, pAKT analysis) or technical replicates (ELISA,
thermal shift assay). For animal experiments, each lane in the western blots and each point in the
graphs corresponds to one mouse unless otherwise noted. For sciatic nerve protein analysis of
chronically treated mice, one FT2Fc treated ZH3mouse was excluded due a technical error in
sample preparation. Otherwise, no samples or data were omitted during the analyses.
Data availability
The raw data from the RNA sequencing experiments are available on the GEO repository
(accession number GSE159948). All data and values that support the findings of this study are
shown in Supporting Information S2 Table.
Results
Generation of a PrP-Fc-fusion protein
The binding of FT to Adgrg6 leads to intracellular accumulation of cAMP, which is essential
in driving the synthesis of proteins and lipids critical for myelin generation and maintenance
PLOS ONE Adgrg6 activation by PrP
PLOSONE | https://doi.org/10.1371/journal.pone.0242137 November 12, 2020 6 / 22
[24]. We sought to investigate if sustained treatment with FT would suffice to constitutively
activate Adgrg6 and thereby restore the reduced promyelination signaling in Prnp ablated
mice (ZH3). Peptides are expected to have a short half-life in vivo, limiting their exposure to
the target tissue. A common strategy to prolong the half-life of peptides is the fusion to larger
molecules such as Fc [25]. We generated a mammalian expression plasmid containing FT
(amino acids 1–50 of mouse PrP) fused with mouse IgG1-Fc at the hinge region, which upon
transfection in cells leads to the expression of the homodimeric fusion protein, FT2Fc (Fig 1A).
The first 22 residues of FT comprise the signal peptide directing FT2Fc for secretion, whereas
residues 23–50 activate Adgrg6 [8]. Murine IgG1-Fc is unlikely to induce inadvertent activa-
tion of the immune system, since the murine IgG1 subclass binds to the inhibitory Fcγ-recep-
tor and does not fix complement [26].
To assess whether FT2Fc is correctly assembled and secreted, we transiently transfected
FreeStyle 293-F cells with the plasmid expressing FT2Fc, resulting in secretion of FT2Fc into
the culture medium. Under non-reducing conditions FT2Fc predominantly existed as a dimer
(56 kD), whereas in the presence of reducing agents (DTT) it migrated as a monomer (Fig 1B).
We confirmed the identity of the secreted protein by western blotting using either anti-mouse
IgG antibodies or a monomeric antibody Fab fragment specifically targeting the KKRPK
domain of FT [23] (Fab83). Both antibodies detected FT2Fc in cell culture supernatant as well
as purified FT2Fc (Fig 1B). To confirm the presence of FT2Fc by additional methods, we per-
formed a sandwich ELISA by capturing FT2Fc with Fab83 and detecting the complex using
anti-mouse IgG antibodies. A serial dilution of cell culture supernatant containing FT2Fc
resulted in a sigmoidal curve, whereas no signal was detected in medium from cells transfected
with the empty vector (Fig 1C). Finally, we immunoprecipitated FT2Fc from cell culture super-
natant using beads coupled with Fab83. Peptides derived from the linear sequence of mouse
PrP were previously used to map the epitope of Fab83 [23]. FT2Fc could be eluted from the
beads with a peptide competing for the Fab83 binding site (amino acids 23–34 of mouse PrP),
but not with a non-competing peptide (amino acids 53–64) (Fig 1D).
Collectively, these results suggest that a correctly assembled FT2Fc fusion protein was
secreted by 293-F cells. We purified FT2Fc from cell culture supernatant by protein A chroma-
tography. The melting temperature of FT2Fc as assessed by thermal shift assay was 74.5˚C at pH
7 (Fig 1E), which is similar to the melting temperature of other purified Fc fragments previously
reported [27,28] and implies high thermal stability of FT2Fc during storage and handling.
FT2Fc activates Adgrg6 signaling in vitro
cAMP signaling is involved in various steps of Schwann cell development (24] and is required
for maintenance of a differentiated state [29]. Adgrg6 signals via cAMP and protein kinase A
to initiate myelination in the PNS [30]. PI3K/AKT-signaling is another pathway involved in
myelination and repair [31]. A link between cAMP and AKT activation has been suggested in
vitro [32]. Activation of Adgrg6 by FT has previously been shown to induce cAMP signaling
in primary Schwann cells, an immortalized Schwann cell line (SW10) and in vivo [8]. In addi-
tion, phosphorylation of AKT has been demonstrated in SW10 cells upon FT treatment [8].
We investigated whether purified FT2Fc can act as a ligand for Adgrg6 in vitro. SW10 cells
were incubated for 20 min with equinormal (half-equimolar where appropriate because of biva-
lency) amounts of either FT2Fc (2.5 μM) or FT (amino acids 23–50 of mouse PrP, 5 μM). cAMP
levels in the cell lysates were measured by ELISA as previously established [8]. Treatment of
wild type SW10 cells (SW10WT) with FT2Fc resulted in a significant increase in the levels of
cAMP, similar to that of FT treated cells. The increase in cAMP was not observed in Adgrg6-ab-
lated cells (SW10ΔAdgrg6) (Fig 2A). Interestingly, we observed a bell-shaped dose-response-curve
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Fig 1. Characterization of FT2Fc. (a) Design of FT2Fc. FT was fused to mIgG1-Fc at the hinge, thereby replacing the antigen-binding
fragment (Fab) and forming a homodimeric Fc-fusion protein. (b) FT2Fc was secreted by 293-F cells after transient transfection and
was present in the cell culture supernatant as a homodimer with a size of 56 kD. Under reducing conditions (+DTT), FT2Fc was present
as a monomer. FT2Fc was detected in western blotting by antibodies targeting the Fc-fragment and a Fab specific for FT (Fab83).
Supernatant from non-transfected cells (NT) was used as negative control. (c) Sandwich ELISA of serially diluted cell culture
supernatant from cells transfected with FT2Fc showed a sigmoidal curve. The optical-density (OD)—dilution curves were fitted using
the four-parameter logistic nonlinear regression model (dashed lines, R2 = 0.94 for FT2Fc). Only background signal was detected in
supernatant from cells transfected with the empty vector control (EVC) or non-transfected cells (NT), or when the plate was coated
with BSA instead of Fab83. (d) Design of the immunoprecipitation assay (left). Western blots of eluates and beads boiled in sample
loading buffer (right). FT2Fc was captured in cell culture supernatant by beads coated with Fab83 and was eluted with a peptide
specifically competing for the Fab83 binding site, but not with a non-competing peptide. The western blot from the beads confirmed
that FT2Fc (size of specific bands marked with
�) was bound to the beads in all conditions. (e) In the thermal shift assay, the unfolding
of FT2Fc with increasing temperature was monitored using a fluorescent dye. The curve was fitted to the Boltzmann equation (dashed
line, R2 = 0.99). The inflection point at 74.5˚C corresponds to the melting temperature of FT2Fc in 20 mM sodium phosphate, pH 7.
https://doi.org/10.1371/journal.pone.0242137.g001
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for FT2Fc in SW10WT cells with a maximum 9-fold increase in cAMP levels at 7 μM, and a drop
in activity at higher doses of FT2Fc (Fig 2B). Bell-shaped dose-response curves have been
described in the literature for ligands of GPCRs and may be related to the dimeric nature of
FT2Fc or receptor desensitization [33,34]. Nonlinear regression analysis revealed an EC50 of
3.49 μM, suggesting that for cAMP signaling in SW10WT cells, FT2Fc exhibited higher efficacy
but slightly lower potency when compared to previously reported results for FT [8]. Then, we
assessed the levels of phosphorylated AKT (pAKT) in SW10 cells upon FT2Fc treatment (Fig
2C). SW10WT cells, but not SW10ΔAdgrg6 cells showed a time-dependent increase in AKT phos-
phorylation when incubated with FT2Fc. These results suggest that FT2Fc acted as a ligand of
Adgrg6 and activated intracellular pathways similarly to FT.
Establishing a functional read out for in vivo assay
In order to monitor if FT2Fc is functional in vivo, we injected ZH3 mice intravenously (i.v.)
with either FT (600 μg) or FT2Fc (10 mg/Kg bodyweight). AKT phosphorylation was
Fig 2. Activation of Adgrg6 by FT2Fc in vitro. (a) FT and FT2Fc elicited an increase in cAMP levels in SW10WT cells, but not in
SW10ΔAdgrg6 cells. cAMP levels were measured 20 min after treatment with 5 μMFT or 2.5 μMFT2Fc. To account for variability in
cAMP levels across cell lines, cAMP was expressed as x-fold change to the average of the controls (PBS and 20 mM sodium
phosphate buffer) for each of the 4 independent experiments. One-way ANOVA for selected comparisons, Sidak’s multiple
comparisons test: in SW10WT FT vs. PBS p = 0.0392, FT2Fc vs. buffer p = 0.0035. In SW10ΔAdgrg6 FT and FT2Fc vs. controls
p> 0.05. (b) SW10WT cells were incubated with increasing concentrations of FT2Fc. cAMP levels increased up to a maximum of a
9-fold change when compared to untreated cells. Nonlinear regression analysis revealed an EC50 of 3.49 μM. For the curve fitting
with the four-parameter logistic regression model (dashed line, R2 = 0.78) only values from 0–8 μM (2–3 replicates per
concentration) were used, because the strongly reduced activity at 9 and 10 μMwould have confounded the analysis. (c) SW10WT,
but not SW10ΔAdgrg6 cells showed a time-dependent increase in AKT phosphorylation upon treatment with 1 μMFT2Fc.
Quantification of 5 independent experiments (left), representative western blot of cell lysates (right). Comparison of SW10WT to
SW10ΔAdgrg6 cells with two-way ANOVA followed by Sidak’s multiple comparisons test: at 10 min, 15 min and 30 min p< 0.0001,
at 5 min and 10 min p> 0.05. ns = not significant.
https://doi.org/10.1371/journal.pone.0242137.g002
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measured in sciatic nerve lysates by western blotting (Fig 3A and 3B). FT injected mice
showed a significant increase in the levels of pAKT after 30 minutes (relative pAKT change
based on quantitative analysis of western blots: control 1.00 ± 0.05(3); FT 1.53 ± 0.11(3);
p = 0.0116; mean ± SEM(n); unpaired t-test), whereas FT2Fc did not elicit an acute increase
Fig 3. Establishment of readout and pharmacokinetics. (a) AKT phosphorylation increased in sciatic nerves of ZH3 mice 30 min
after injection of 600 μg FT. As control (ctrl), mice were injected with an inactive peptide, in which lysine residues have been
replaced with alanine residues [8]. In mice injected with FT2Fc (10 mg/Kg), no significant change in AKT phosphorylation was
detected after 30 min when compared to mIgG injected mice. Square brackets in western blots indicate left and right sciatic nerves
taken from one mouse. The average value was used for quantification. (b) AKT phosphorylation did not increase after six
consecutive FT2Fc injections. (c) Western blots of sciatic nerve cell lysates fromWT and ZH3 mice. ZH3mice exhibited a decrease
in sciatic nerve Egr2 levels and a concomitant increase in GFAP and c-Jun levels. (d) ZH3 mice were i.v. (n = 2) or i.p. (n = 2)
injected with FT2Fc (5 mg/Kg) and FT2Fc serum levels were monitored by western blotting with Fab83 at 1, 6 and 24 h after
injection. A serum sample from a mouse injected with mIgG (5 mg/Kg) was used as negative control. The early serum level–time
course was similar in i.v. and i.p. injected mice. (e) ZH3 mice were i.p. injected with 10 mg/Kg FT2Fc and blood samples were
collected from 1 to 8 days post injection. The elimination of FT2Fc from serum followed first order elimination kinetics. (f) Serum
level values (normalized to the level at 23 h post injection) were plotted on a semi-logarithmic graph and fitted with nonlinear
least-squares analysis (dashed line, R2 = 0.92) to calculate the terminal serum half-life of FT2Fc. The serum half-life was estimated
to be 45 h with a 95% confidence interval of 37–58 h. The number of mice investigated per time point (n) is indicated above the
points.
https://doi.org/10.1371/journal.pone.0242137.g003
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in AKT phosphorylation (control 1.00 ± 0.04(4); FT2Fc 0.99 ± 0.02(4); mean ± SEM(n);
p = 0.8560; unpaired t-test). Additionally, no significant increase in pAKT levels could be
detected after 6 days of FT2Fc treatment (control 1.00 ± 0.07(3); FT2Fc 1.14 ± 0.02(3);
mean ± SEM(n); p = 0.1356; unpaired t-test). This result was not unexpected since FT2Fc is
a larger molecule and predicted to diffuse at a slower rate to the target tissue as compared to
FT. Accordingly, acute in vivo activity might be difficult to capture with our assay. We
therefore proceeded with long-term FT2Fc treatment of ZH3 mice to assess therapeutic
effects upon chronic exposure. As a read-out we aimed at identifying early protein expres-
sion changes. The transcription factor Egr2 (Krox20) is required for myelin maintenance
[35] and has previously been shown to be decreased in ZH3 mice [8]. We collected sciatic
nerves from ZH3 mice at various ages and found that Egr2 expression levels were lower
when compared to wild type (WT) C57BL6/J mice (Fig 3C). The protein markers of repair
Schwann cells, c-Jun and GFAP, showed an early increase in ZH3 mice when compared to
WT mice. (Fig 3C). We planned to use these early signs of peripheral nerve damage as a
readout to assess the effect of FT2Fc treatment in a chronic prophylactic treatment study.
In vivo pharmacokinetics of FT2Fc
To determine a suitable treatment regime for the in vivo experiments, we performed pharma-
cokinetic studies with FT2Fc in ZH3 mice. ZH3 mice were injected either i.v. or intraperitone-
ally (i.p.) with FT2Fc (5 or 10 mg/Kg). Blood samples were collected at different time points
after a single injection (1 h up to 8 days) and FT2Fc levels were monitored in the serum by
western blotting with Fab83. The distribution phase of FT2Fc was similar after 1 h post injec-
tion when comparing i.v. and i.p. injection (Fig 3D). Thus, we proceeded with i.p. injections
for further experiments. In the elimination phase, FT2Fc followed first order elimination kinet-
ics with an exponential decrease of serum levels over time (Fig 3E). Based on the serum level–
time profile during the elimination phase the terminal serum half-life of FT2Fc was estimated
to be 45 h (Fig 3F). This duration was deemed sufficiently long for chronic FT2Fc treatment in
mice.
Chronic treatment fails to rescue early molecular changes in sciatic nerves
of ZH3 mice
We next examined if chronic administration of FT2Fc in ZH3 mice would rescue the demye-
linating neuropathy. We designed a prophylactic study in which treatment was started at 1
month of age, when signs of demyelination are not yet present in ZH3 mice [1,36] (Fig 4A).
ZH3 mice were injected i.p. three times per week (based on the 45 h half-life of FT2Fc) with 8
mg/Kg FT2Fc or control treatment for a total of 4 months. We additionally included WTmice,
which received the same treatment as ZH3 mice. Blood samples were collected at 1 and 2
months after treatment start. Serum levels of FT2Fc were comparable at both time points (Fig
4B), indicating that the half-life of FT2Fc did not decrease over time and that mice did not gen-
erate antibodies against FT2Fc [37,38]. Furthermore, we detected FT2Fc in sciatic nerve
homogenate by western blotting (S2 Fig). There was no difference in body weight between the
treatment groups (Fig 4C). At the end of the chronic treatment mice were sacrificed and sciatic
nerves were collected for protein analysis (Fig 4D). GFAP levels were increased whereas Egr2
levels were decreased in sciatic nerves of ZH3 mice when compared toWTmice. However,
treatment with FT2Fc did not rescue the increase of GFAP nor the decrease in Egr2 levels.
C-Jun levels were not increased in ZH3 mice when compared to WTmice, nor did FT2Fc
treatment change c-Jun levels. As expected at the age of 5 months, sciatic nerves of ZH3 mice
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showed no conspicuous morphological signs of demyelination [1,36], and no morphological
alterations were induced by FT2Fc treatment (Fig 4E and 4F).
Certain phenotypes in early generations of PrP knockout mice were found to be poorly
reproducible and seem to represent genetic confounders [36,39]. The development of periph-
eral demyelination, however, was confirmed in ZH3 mice that have a pure C57BL6/J back-
ground [36]. Based on the time course of macrophage infiltrations, the disease seemed to
manifest later than described in previous reports on mice with mixed genetic background [1].
The early reduction in nerve conduction velocity has not been re-assessed in ZH3 mice. In
electrophysiological investigations performed at the end of FT2Fc treatment, we did not detect
a decrease in nerve conduction velocity in ZH3 mice when compared to WTmice (Fig 5A and
5B). This suggests that the ZH3 mice used in the experiments reported here had not developed
electrophysiological signs of demyelination at the age of 5 months and that these investigations
were not a telling readout for a treatment effect in our study. Indeed, we could not detect any
differences in nerve conduction velocity or compound muscle action potential amplitude
between treatment groups (Fig 5A–5C). No polyphasic compound muscle action potentials
were recorded, and electromyography of the foot muscles showed no pathological spontaneous
activity.
FT2Fc treatment elicits gene expression changes which are deleterious in
skeletal muscle
In the absence of a rescue of protein markers in ZH3 mice upon chronic FT2Fc treatment, we
postulated that FT2Fc either did not reach the precise destination in the sciatic nerve or did
not activate the desired myelinotrophic signalling pathways. To assess FT2Fc induced changes
in an unbiased and genome-wide manner, we investigated the transcriptome of sciatic nerves
from FT2Fc treated and control mice by RNA sequencing. Additionally, we sequenced sciatic
nerves of untreated WT and ZH3 mice at 4 and 13–15 months.
Unsupervised clustering based on the 100 genes with the highest variance across all samples
showed a separation between FT2Fc treated and control treated ZH3 mice (Fig 6A). Based on
published datasets, we assembled a list of genes that are important for the repair Schwann cell
phenotype [40]. ZH3 mice showed a mild increase of these genes at 4 months and a strong
upregulation at 13–15 months (Fig 6B). We did not observe a change in expression of any of
Fig 4. Chronic administration of FT2Fc. (a) Design of the prophylactic treatment experiment in ZH3 andWTmice. Starting at 1
month of age, ZH3 andWTmice were injected with FT2Fc (or control treatment) 3 times per week until the age of 5 months. Bars with
grey shades show expected changes in protein levels with dark and light grey meaning high and low levels, respectively. (b) FT2Fc serum
levels were measured 2 days after the last injection. Representative western blot showing serum levels for 4 ZH3 mice after 1 and 2
months of treatment. FT2Fc serum levels did not decrease after 2 months of treatment when compared to the level at 1 month (n = 8,
paired t-test, p = 0.3529), suggesting that FT2Fc half-life was unaltered. (c) Bodyweight was not significantly different between treatment
groups (as analysed by two-way repeated measures ANOVA, p> 0.05). Body weight was recorded at every injection time point for all
the mice in the chronic treatment study and is here shown for week 1 to 6 of treatment as percentage of the body weight at treatment
start (reference). (d) Representative western blots and quantification for levels of GFAP, c-Jun and Egr2 in sciatic nerves. GFAP levels
were significantly higher in ZH3 mice compared to WTmice, but no significant change was induced by FT2Fc compared to buffer
treatment (one-way ANOVA for selected comparisons, Bonferroni’s multiple comparisons test: ZH3 vs. WT for buffer treated mice
p = 0.0345, for FT2Fc treated mice p = 0.0343. FT2Fc vs. buffer treated mice, both ZH3 andWT p> 0.05). C-Jun levels were not
decreased in ZH3 compared to WTmice, and no significant change in c-Jun levels was induced by FT2Fc treatment (one-way ANOVA
for selected comparisons, Bonferroni’s multiple comparisons test, p> 0.05). Egr2 levels were significantly lower in ZH3 mice compared
to WTmice, but FT2Fc treatment did not induce a significant change in any genotype (one-way ANOVA for selected comparisons,
Bonferroni’s multiple comparisons test: ZH3 vs. WT for buffer treated mice p< 0.0001, for FT2Fc treated mice p = 0.0044. FT2Fc vs.
buffer treated mice, both ZH3 andWT p> 0.05). Protein levels were expressed as fold change the average level in buffer treated ZH3
mice. (e) Toluidine-blue stained semithin sections of sciatic nerves. No difference in fibre morphology was detected between treatment
groups in our ZH3 mouse specimens. Scale bar 50 μM. (f) Number of myelinated axons per mm2 in sciatic nerves of ZH3 mice revealed
no difference between treatment groups (comparison of FT2Fc and IgG treated to buffer treated mice by one-way ANOVA followed by
Dunnett’s multiple comparisons test, p> 0.05). ns = not significant.
https://doi.org/10.1371/journal.pone.0242137.g004
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these genes upon FT2Fc treatment (Fig 6B), which is in line with the absence of changes in
repair Schwann cell markers at the protein level. Instead, functional gene ontology analysis
revealed that FT2Fc specifically induced a downregulation of genes associated with muscle
contraction and organization of actin filaments and sarcomeres (Table 1 and Fig 6C). Our sci-
atic nerve bulk RNA sequencing analysis did not allow us to infer in which cell type these
genes were differentially expressed. We therefore explored previously published single cell
RNA sequencing data from healthy and injured sciatic nerves [41]. Several genes that were dif-
ferentially expressed upon FT2Fc treatment are enriched in perivascular cells and vascular
smooth muscle cells (Des, Sh3bgr, Tpm1, Ldb3) or belong to mesenchymal cell clusters
(Tnnt3, Cmya5, Pygm, Eno3). In contrast, genes that are expressed specifically in Schwann
cells did not change their expression profile upon FT2Fc treatment.
These unexpected experimental observations led us to consider previous studies that
showed a necrotizing myopathy in mice overexpressing PrP [14,15]. We wondered whether
treatment with FT2Fc may have mimicked PrP overexpression and induced gene expression
changes similar to those involved in the myopathy phenotype rather than acting as a ligand to
Adgrg6. We therefore compared the transcriptomic changes in FT2Fc treated sciatic nerves to
gene expression changes in the tibialis anterior muscle upon inducible PrP overexpression (Fig
7A and 7B). While the overall correlation between the datasets was low, a noteworthy overlap
was observed among the downregulated genes. Specifically, 35% of genes that were signifi-
cantly downregulated (FDR< 0.05) by FT2Fc were also downregulated in PrP overexpressing
muscle. This suggests that FT2Fc treatment might have triggered pathways similar to those
caused by PrP overexpression. However, the muscle tissue of FT2Fc-treated mice did not show
any myopathic changes (Fig 7C).
In conclusion, the transcriptomic analysis showed that chronically administered FT2Fc had
reached the sciatic nerve and elicited a specific pharmacodynamic effect. Yet the detected gene
expression changes did not indicate an activation of Adgrg6-mediated myelination signalling.
Fig 5. Electrophysiological studies. All tests and calculations were done with the examiners masked as to treatment and strain
allocation. (a) Motor nerve conduction velocities (NCV) for WT and ZH3 mice. There was no significant difference betweenWT
and ZH3 mice, or between FT2Fc treated and buffer treated mice (one-way ANOVA for indicated comparisons, Bonferroni’s
multiple comparisons test, p> 0.05). (b) Compound sensory NCV (csNCV) for WT and ZH3 mice. Again, there was no significant
difference betweenWT and ZH3 mice, or FT2Fc treated and buffer treated mice (one-way ANOVA for indicated comparisons,
Bonferroni’s multiple comparisons test, p> 0.05). (c) The ratio of proximal to distal compoundmuscle action potential (CMAP)
amplitude was not significantly different when comparing ZH3 toWTmice or FT2Fc to buffer treated mice (one-way ANOVA for
indicated comparisons, Bonferroni’s multiple comparisons test, p> 0.05). ns = not significant.
https://doi.org/10.1371/journal.pone.0242137.g005
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Instead, the downregulation of cytoskeleton proteins and contractile elements was reminiscent
of the toxic effects of PrP overexpression.
Discussion
The treatment options for many peripheral nerve diseases are limited, and despite the remark-
able ability for repair in the PNS, regeneration in intrinsic peripheral neuropathies or after
nerve injury is often incomplete. Schwann cells are crucial for the function and maintenance
of peripheral nerves and may represent interesting targets to boost the endogenous repair
capacity of the PNS.
Many approved drugs target G-protein coupled receptors, and therefore Adgrg6 may repre-
sent an attractive potential target to stimulate repair in peripheral neuropathies or after nerve
Fig 6. RNA sequencing of sciatic nerves from FT2Fc treated mice. (a) Hierarchical clustering analysis based on the 100 genes with
the highest variance across all samples showed a separation between FT2Fc treated mice and control mice (n = 4 per treatment). (b)
Heatmap of the selected repair Schwann cell genes. The red-blue colour key is based on the row-wise Z-scores. 4 months old ZH3 mice
(n = 3) showed a mild, 13–15 months old ZH3 mice (n = 4) a pronounced upregulation of these genes when compared to age-matched
WTmice. No difference was detected in FT2Fc treated ZH3 mice (n = 4) compared to buffer treated mice (n = 4). (c) Volcano plot
showing differentially expressed genes in sciatic nerves of FT2Fc treated compared to buffer treated mice. Genes with FDR< 0.05 were
considered significantly up- or downregulated (43 downregulated genes, 1 upregulated gene). Genes involved in actin binding are
labelled in the plot. Log2FC = log2 fold change.
https://doi.org/10.1371/journal.pone.0242137.g006
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damage. We here exploited a natural Adgrg6 agonist, PrP, to design a molecule targeting
Adgrg6 for the treatment of peripheral nerve disease. The fusion of PrP’s myelinotrophic
domain to an Fc-fragment (FT2Fc) yielded a molecule with sufficiently long half-life, making it
feasible for in vivo treatment. Several Fc-fusion based drugs (also termed immunoadhesins)
have been approved for therapeutic use in humans [42]. Importantly, immunoadhesins are
intrinsically dimeric. In the case of sufficiently dense targets, this allows for two-point binding.
The theoretical avidity of such binding corresponds to the product of the monomeric binding
affinity and can be extremely high [43,44].
We attempted a proof-of-principle study by prophylactically administering FT2Fc to ZH3
mice, which develop a slowly progressive peripheral demyelinating neuropathy during their
lifetime [1]. However, FT2Fc did not activate the desired pro-myelination signaling pathways
in our treatment study and we failed to detect a therapeutic effect in vivo. Instead, we detected
a downregulation of cytoskeleton-related genes, reminiscent of the changes seen in skeletal
muscle of PrP overexpressing mice developing a necrotizing myopathy [14]. While compari-
son of the transcriptional changes in different tissues as was presented here must be inter-
preted with great caution, the possibility of myotoxicity induced by a PrP-based agent should
not be discounted. Early studies suggested that Adgrg6 is expressed in muscle tissue [45], but a
recent study objected that Adgrg6 detected in muscle homogenate derived from endothelial
cells instead of muscle cells [46]. Thus, it remains unclear whether the toxic effect of PrP is
mediated by Adgrg6 or by other interaction partners.
Myelination and the maintenance of myelin are controlled by tightly balanced reciprocal
signalling between Schwann cells, axons and extracellular matrix [47]. Inappropriate or exces-
sive activation of involved signalling pathways can have detrimental effects on myelin develop-
ment, maintenance or repair [48,49]. In our chronic treatment study, FT2Fc did not negatively
affect myelin maintenance as assessed by biochemical, morphological and electrophysiological
investigations.
Limitations of this study
Several reasons may explain the lack of a demonstrable treatment effect of FT2Fc in vivo.
Peripheral nerve damage in ZH3 mice at the age investigated here was only mild, as indicated
by the lack of electrophysiological and morphological signs of demyelination. But even at the
molecular level, no amelioration of the early protein and RNA changes was achieved by chronic
Table 1. Biological process (BP) enriched categories obtained by gene ontology analysis.





Muscle contraction 18 < 0.00001 Tmod4; Actn3; Trdn; Mybpc1; Myom1; Cacna1s; Tpm2; Trim63; Ryr1; Myom2; Myh2; Mybpc2;
Ttn; Actn2; Myh7; Myh1; Myh4; Myl1
Sarcomere organization 13 < 0.00001 Casq1; Tcap; Mybpc1; Mypn; Ldb3; Myom1; Neb; Myom2; Mybpc2; Mybph; Ttn; Actn2; Klhl41
Actin filament organization 10 < 0.00001 Tmod4; Mybpc1; Myom1; Tpm2; Myom2; Pdlim3; Tpm1; Mybpc2; Mybph; Ttn
Glycogen metabolic process 5 0.001 Phkg1; Pygm; Agl; Phka1; Ppp1r3a
BP enriched category Upregulated genes P
adjusted
List of genes
positive regulation of B cell
activation
6 < 0.00001 Ighv4-1; Ighv7-1; Ighv1-80; Ighv1-82; Ighv2-9-1; Ighv10-1
immunoglobulin production 3 0.02 Igkv17-121; Igkv2-112; Igkv1-110
Gene ontology analysis of differentially expressed genes in sciatic nerves of FT2Fc treated compared to buffer treated mice. The complete list of overrepresented
categories is shown in S1 Table.
https://doi.org/10.1371/journal.pone.0242137.t001
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FT2Fc treatment. We wondered whether this may have been caused by disadvantageous phar-
macokinetic properties of FT2Fc. We detected FT2Fc in sciatic nerve lysate by western blotting,
but this did not allow us to conclude that FT2Fc reached Adgrg6 on Schwann cells. It is possible
that, as a relatively large molecule, FT2Fc might not have reached Adgrg6 in sufficient
Fig 7. Genes downregulated by FT2Fc show similar changes in PrP-overexpressing muscle. (a) Log2 fold change
(log2FC) for significantly downregulated genes (n = 43, based FDR< 0.05) in sciatic nerves of FT2Fc treated compared to
buffer treated mice and corresponding log2FC in tibialis anterior muscle of PrP overexpressing mice. � marks genes
which were also significantly downregulated in muscle based on FDR< 0.05 (n = 15). Grouping of genes according to
common functions was based on a manual search in the UniProt database. (b) Scatterplot comparing gene expression
changes in muscle of PrP overexpressing mice and sciatic nerves of FT2Fc treated mice. 1229 and 43 genes were
significantly (FDR< 0.05) downregulated in muscle and nerve, respectively, with 15 of these genes overlapping. Grey line
represents linear regression. Pearson’s correlation coefficient r = 0.09. (c) 10 μMGomori trichrome stained frozen
sections of gastrocnemius muscle from FT2Fc and buffer treated ZH3 mice. Muscle fibre morphology was similar in
buffer and FT2Fc treated mice. No myopathic changes were detected in FT2Fc treated mice. Scale bar 20 μM.
https://doi.org/10.1371/journal.pone.0242137.g007
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quantities. However immunoglobulins, which are three times larger than FT2Fc, were reported
to cross the blood-nerve-barrier [50]. Alternatively, an uneven distribution caused for example
by binding of FT2Fc to Fcγ-receptors in various tissues could have sequestered FT2Fc from the
peripheral nerves. Reassuringly, the transcriptomic analysis revealed specific gene expression
changes in the sciatic nerves of FT2Fc treated mice, suggesting that FT2Fc reached its destina-
tion and was pharmacodynamically active. Yet FT2Fc did not activate the desired signaling
pathways. The dimeric nature of FT2Fc could alter its biological activity when compared to
monomeric FT and endogenous PrP. A soluble dimeric full-length PrP was previously shown
to have different properties that endogenous PrP with regard to its pathologic structural conver-
sion [51]. Whether the dimeric full-length PrP is able to sustain its physiological function in
myelin homeostasis has not been investigated by Meier et al. Moreover, oligomerization of
receptors including adhesion G-protein coupled receptors, contributes to biased signaling
[52,53]. A dimeric ligand such as FT2Fc may exhibit novel binding properties, induce receptor
homo- or hetero-oligomerization and activate different intracellular signaling pathways in vivo.
Our in vitro studies with FT2Fc showed increased cAMP elevation and prolonged AKT phos-
phorylation when compared to FT. While we interpreted these results as evidence for a high
potency and stability of FT2Fc, they could also indicate biased agonism and contribute to the
unexpected pharmacodynamics properties of FT2Fc in vivo [54]. Interestingly the bell-shaped
dose-response curve observed here was not seen when cells were treated with FT [8] and could
indicate a novel activity of dimeric FT2Fc different from that of monomeric FT.
Conclusions
To the best of our knowledge, this study represents the first attempt to target Adgrg6 activation
for treating peripheral nerve demyelination in vivo. Although our treatment regimen was not suc-
cessful, Adgrg6 should not be discarded as a possible therapeutic target for peripheral nerve dis-
eases. For example, FT2Fc could be tested in more rapidly progressive models of peripheral
demyelination such as autoimmune peripheral neuropathies [55]. Moreover, the pharmacokinet-
ics and pharmacodynamics of Adgrg6 ligands might be optimized by modifications such as cou-
pling FT to polyethylene glycol or dendrimers or by designing a bispecific molecule targeting
Adgrg6 and thereby directing FT to its receptor. Such strategies may be hampered by the blood-
nerve barrier, which may hinder access of the therapeutic compound to Adgrg6 on Schwann
cells. Encouragingly, two studies have identified novel agonists of Adgrg6 by drug screening in
zebrafish [56,57]. Such small-molecule drugs may exhibit better penetration into nerves than the
biological macromolecule studied here and could be leveraged to target Adgrg6 in vivo. Future
studies should explore these alternative therapeutic strategies utilizing a variety of disease models.
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main figures.
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S2 Fig. Detection of FT2Fc in tissue homogenates. Tissue lysates from a mouse chronically
treated with FT2Fc were subjected to western blotting with Fab83. FT2Fc was detected in all
organs (100 μg of total protein) and in the serum (diluted 1:100 in PBS). Calnexin was used as
a loading control. The mouse was sacrificed 2 days after the last injection. ��: dimer. �: mono-
mer.
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S1 Table. Complete list of overrepresented GO categories in sciatic nerves of FT2Fc treated
compared to buffer treated mice.
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